

**Henry A. Punzi, MD, FCP, FASH**

Medical Director Clinical Trials  
Trinity Hypertension & Metabolic Research Institute  
Attending Physician, Internal Medicine Department  
Baylor Scott & White Medical Center  
Private Practice, Internal Medicine and Hypertension  
Carrollton, Texas  
Clinical Assistant Professor  
UT Southwestern Medical Center  
Dallas, Texas

Henry A. Punzi, MD, FCP, FASH is in private practice and does clinical research at the Trinity Hypertension & Metabolic Research Institute in Carrollton, Texas. He currently is a Clinical Assistant Professor at UT Southwestern Medical Center in Dallas, an Associate Clinical Professor Texas Women's University, Dallas, Texas and is an attending physician of Internal Medicine at Baylor Scott & White Medical Center, in Carrollton, Texas.

Dr. Punzi received his medical degree and postgraduate training from the University of Buenos Aires, Argentina and completed fellowships in clinical and research hypertension at the University of Texas Southwestern Medical School, Parkland Memorial Hospital, and St. Paul Hospital, all in Dallas.

A fellow of both the American College of Clinical Pharmacology and the American Society of Hypertension, Dr. Punzi is a member of the Council for High Blood Pressure Research of the American Heart Association, the American Society of Hypertension, and the American Society for Clinical Pharmacology and Therapeutics. He is Academic Editor of the International Journal of Hypertension, served on the Board of Directors of the Consortium of South East Hypertension Centers and currently serves on the Board of Directors of the Inter-American Society of Hypertension. He is an Editorial Board Member of the The Open Hypertension Journal and also serves as a reviewer for the following journals: *Journal of Clinical Hypertension, Hypertension, The American Journal of Hypertension, Journal of Human Hypertension, Experimental Hypertension, International Journal of Hypertension, Integrated Blood Pressure Control, Therapeutic Advances in Cardiovascular Disease, Drugs, Expert Review of Cardiovascular Therapy, Journal of Clinical Research and Pharmacoepidemiology, Journal of Geriatric Cardiovascular Medicine, Aging and Drugs, Cardiovascular Expert Review, Journal of Cell Adhesion and Migration, Drugs of Today, Cell Biochemistry and Function, Cardiovascular Diagnosis Therapy, Journal of Biomedicine and Pharmacology and the Journal of the Renin-Angiotensin Aldosterone System*. Dr. Punzi has been involved in Clinical Research since 1986 and has been a Principal Investigator in 150 clinical trials, highlighted by participating in the VALHEFT, ALLHAT, VALUE, SPRINT and SPRINT MIND Trials. He served on the Inclusion, Exclusion and Retention Committee of the NIH sponsored SPRINT/SPRINT MIND study.

Dr. Punzi served 15 years as the Chairman of the editorial committee for the *Dallas Medical Journal*. He has published over 80 articles in medical journals and written ten book chapters. He has written a book on hypertension and served as series editor for three volumes of *Clinical Cardiovascular Therapeutics*. He currently is completing his second book, *The ABCD of Hypertension* for Krager Publishing.

## CURRICULUM VITAE

Henry Anthony Punzi, MD, FCP, FASH

BUSINESS ADDRESS: Trinity Hypertension & Metabolic Research Institute  
Punzi Medical Center  
1932 Walnut Plaza  
Carrollton, Texas 75006  
Phone Number: (972) 478-7700  
Facsimile Number: (972) 478-7701  
E-Mail: [Punzimedcenter@aol.com](mailto:Punzimedcenter@aol.com)  
Web Site: [www.punzimedicalcenter.com](http://www.punzimedicalcenter.com)

DATE OF BIRTH: April 21, 1958

### EDUCATION:

1971-74: Greece Arcadia High School. Rochester, New York  
1974-78: University Of Buenos Aires, Faculty of Medicine,  
Buenos Aires, Argentina  
1978-81: University Hospital de Clinicas "Jose de San Martin",  
Buenos Aires, Argentina, Internal Medicine Residency  
1981-82: Scott & White Memorial Hospital, Temple Texas  
Pathology Internship  
1982-83: Wadley Institute of Molecular Medicine, Granville C. Morton Hospital  
Dallas, Texas. Fellowship Hematology/ Oncology  
1983-84: University of Texas Health Science Center, Southwestern Medical School,  
Parkland Memorial Hospital, Dallas, Texas  
Fellowship Clinical and Research Hypertension  
2007-2009 MBA, Texas Tech University, Lubbock, Texas

### CURRENT POSITION:

1984-Present: Private Practice, Internal Medicine and Hypertension  
Carrollton, Texas  
1984-Present: Medical Director Clinical Trials. Trinity Hypertension & Metabolic  
Research Institute, Carrollton, Texas  
1985-Present: Attending Physician, Internal Medicine Department. Baylor Scott & White  
Medical Center Carrollton, Texas

### ACADEMIC POSITION

2004-Present: Associate Clinical Professor  
Texas Women's University  
Dallas, Texas  
2010-Present: Clinical Assistant Professor  
University of Texas Southwestern Medical School  
Dallas, Texas

#### HOSPITAL POSITIONS:

##### Emergency Department Staff:

- 1982: - Matagorda County Hospital, Bay City, Texas.  
- Silsbee Doctor's Hospital, Silsbee, Texas.  
- T.L. Goodnight Memorial Hospital, Caldwell, Texas.  
- Grant Buie Memorial Hospital, Hillsboro, Texas.  
- Newburn Memorial Hospital, Jacksonville, Texas.  
- Fannin County Hospital, Bonham, Texas.
- 1983: - St. Joseph's Hospital, Paris, Texas  
- Stevens Park Hospital, Dallas, Texas.

##### Internal Medicine Department:

- 1984: - Granville C. Morton Hospital, Dallas, Texas.  
- Shiloh Park Hospital, Garland, Texas.
- 1985: - Trinity Medical Center, Carrollton, Texas.
- 1986: - Southwest Dallas Hospital, Dallas, Texas.

#### APPOINTMENTS:

- 1979: English/ Spanish Translator, Merck, Sharp, & Dohme Laboratories, Buenos Aires, Argentina.
- 1980: University of Buenos Aires, Argentina, Clinical Instructor, Medical English Department.
- 1982-86: Visiting Physician, Adult Alcohol Rehabilitation Program, Salvation Army, Dallas, Texas.
- 1983: President, House Staff Association, Granville C. Morton Cancer and Research Hospital, Dallas, Texas.
- 1983-85: Sunshine Kids Foundation, Houston, Texas.  
Founding Staff Physician.
- 1984: Texas State Delegate to the American Medical Association, RPS Section's Meeting, Chicago, Illinois.
- 1983-84: Treasurer, Dallas Society of Clinical Hypnosis, Dallas, Texas.
- 1984: Texas Delegate to the American Medical Association, RPS Section Meeting, Honolulu, Hawaii.
- 1984-85: Resident Representative, Board of Trustees, Educational Commission for Foreign Medical Graduates
- 1984-85: Health Officer, Dallas County Health Department, Lew Sterret Correctional Facility, Dallas, Texas.
- 1984-86: Medical Director, Drug Abuse Rehabilitation Program, "Help is Possible" Dallas, Texas.
- 1984-86: Alternate Delegate, Dallas County Medical Society, Dallas, Texas.
- 1987-02: Delegate, Dallas County Medical Society, Dallas, Texas.

- 1985-87: Chairman, Institutional Review Board, Trinity Medical Center, Carrollton, Texas.
- 1985-87: Founding Board Member, Northwest Medicare IPA, Farmer's Branch, Texas.
- 1985-86: Chief of Staff, Internal Medicine Department, Trinity Medical Center, Carrollton, Texas.
- 1986-87: Special Friends Foundation, Staff Physician.
- 1986-87: Chairman, Board of Trustees, DARCO Drug Service, Inc. Drug Rehabilitation Program, Dallas, Texas.
- 1986-87: Texas State Delegate to the American Medical Association, Young Physicians Section.
- 1986-87: Advisory Board, Technical Internship Program, Carrollton/ Farmer's Branch Independent School District.
- 1986-87: First Western National Bank Advisory Board, Carrollton, Texas.
- 1986-89: Texas Industrial Accident Board, Medical Arbitration, District 4.
- 1987: Texas Medical Foundation Physicians Advisor.
- 1987: Chairman, Young Physician Section, Texas Medical Association.
- 1987-88: Board of Trustees American College of International Physicians.
- 1989: Reviewer, Geriatric Cardiovascular Medicine
- 1991: Reviewer, Journal of Clinical Research and Pharmacoepidemiology
- 1994: Reviewer, Journal of Human Hypertension
- 1996: Editorial Board, Dallas Medical Journal
- 2004: Reviewer, Journal Drugs
- 2005: Reviewer, American Journal of Hypertension
- 2005: Reviewer, Journal of Clinical Epidemiology
- 1997-08: Chairperson, Editorial Board, Dallas Medical Journal
- 2008: Member, Communications Committee, Dallas County Medical Society
- 2009: Reviewer: Journal of the Renin-Angiotensin Aldosterone System
- SPECIAL TRAINING:
- 1980-81: Research Assistant, Hypertension Division Vth Cathedra of Internal Medicine, University Hospital de Clinicas, "Jose de San Martin," Buenos Aires, Argentina.
- 1984-90: Instructor "Advanced Cardiac Life Support".
- 1986-Present: Investigator- Phase II-IV Clinical Research Studies.

SOCIETY MEMBERSHIPS:

- 1982: Dallas County Medical Society  
Texas Medical Association  
American Medical Association  
National Association of Residents and Interns  
Inter-American College of Physicians and Surgeons
- 1983: Dallas Society of Clinical Hypnosis
- 1983: North Texas Association of Latin American Physicians

- 1984: American College of Emergency Physicians  
The New York Academy of Sciences  
The Hispanic/ American Society of Hypertension
- 1985: Texas Society of Internal Medicare  
The American Society of Internal Medicine  
Associates of Clinical Pharmacology
- 1986: American College of Medicine  
The American Society of Hypertension  
Argentine Intra-University Society of Internal Medicine
- 1987: American College International Physicians  
American College of Physicians
- 1988: American College of Clinical Pharmacology  
Inter-American Society of Hypertension  
American Society for Clinical Pharmacology and Therapeutics
- 1989: Member, Council for High Blood Pressure Research,  
American Heart Association
- 2011: Fellow American Society of Hypertension

#### COMMITTEES

- 1983: Pain Committee, Granville C. Morton Cancer and Research Hospital,  
Dallas, Texas.
- 1983-84: Texas Political Action Committee, Board Member.  
Texas Medical Association, Committee on Cancer,  
Resident Representative.
- 1983: Credentials Committee, Resident Physician Section. American Medical  
Association Interim Meeting, Los Angeles, California.
- 1984: Tellers Committee, Resident Physician Section, American Medical  
Association, Chicago, Illinois.
- 1983-85: Resident Representative, American Medical Association, Ad Hoc  
Committee on Foreign Medical Graduates.
- 1985-86: Member, American Medical Association Ad Hoc Committee on Foreign  
Medical Graduates.
- 1985: Tellers Committee, Texas Medical Association, House of Delegates  
Meeting, San Antonio, Texas.
- 1986-87: Chairman, Health Services Committee, Metrocrest Chamber of Commerce
- 1986-89: Texas Medical Association, Committee on Association Insurance  
Programs.
- 1986: Texas Medical Association, Steering Committee, Young Physicians  
Section.
- 1987: Pharmacy and Therapeutics Committee, Trinity Medical Center,  
Carrollton, Texas.

- 1987: Medical Records and Utilization Review Committee, Trinity Medical Center, Carrollton, Texas.
- 1987: Fundacion Argentina Para Estudios en Hipertension Arterial, Buenos Aires, Argentina, Scientific and Educational Advisory Committee.
- 1987: Reference Committee Legislation, Texas Medical Association, Interim Session, House of Delegates.
- 1989: Texas Medical Association Insurance Trust
- 1990: Interprofessional Mental Health Liaison Committee for Texas
- 1990: Advisory Board, Willow Bend Polo Club, Dallas, Texas.
- 1991: Ethics Committee, Trinity Medical Center, Carrollton, Texas.
- 1991: Texas Medical Association, Reference Committee on Constitution and Bylaws.
- 1992: Texas Medical Association, Reference Committee on Public Health and Scientific Affairs
- 1998: Chairperson Institutional Review Board, Trinity Medical Center
- 2010 National Institute of Health SPRINT Study: Member of the Recruitment, Retention and Adherence Subcommittee.

#### HONORS AND AWARDS

- 1980: Graduated with Honors, University of Buenos Aires, Faculty of Medicine, Buenos Aires, Argentina. Appointed Master of Ceremonies of First Gala Graduate Party, University of Buenos Aires, Faculty of Medicine.
- 1983-84: Guest Host, Television Talk Show, "Ayuda e Informacion," Channel 33, Dallas, Texas.
- 1984: Pfizer Laboratories, Speakers Program, "Hypertension".
- 1984: Medical Columnist, Newspaper, "La Aurora", Dallas, Texas.
- 1984: Guest Lecturer, University of Buenos Aires Faculty of Medicine, Buenos Aires, Argentina.
- 1985: American Medical Association, Certificate of Recognition for Outstanding Service in Resident Physician Section.
- 1986: Volunteer Ski Instructor, Handicap Skiing Program, Winter Park, Colorado.
- 1986: Recognition for Outstanding Service in Technical Internship Program by Board of Directors of Carrollton/Farmers Branch Independent School District by Resolution passed on June 12, 1986.
- 1986: Guest Speaker, Television Talk show, "Texas Accents", Channel 33, Dallas, Texas.
- 1986: E.R. Squibb Laboratories, Speakers Program, "Hypertension".
- 1986: Guest Lecturer in Universities of Buenos Aires, Cordoba and Bahia Blanca, Faculty of Medicine, Argentina.
- 1986: Texas Medical Association, Certificate of Appreciation for outstanding service performed in the Committee on Association Insurance Programs.
- 1987: Knoll Pharmaceutical Speakers Program, "Hypertension."
- 1987: Smith Kline and French Pharmaceutical Speakers Program, "Hypertension".

- 1987: Guest Lecturer, "Hypertension", University of Buenos Aires Argentina, Fourth University Congress of Internal Medicine, Rosario, Argentina.
- 1988: Television Interview on Diabetes Mellitus for Channel 49, Dallas, Texas.
- 1988: A.H. Robbins, Speakers Program.
- 1988: Texas Medical Association Award, Outstanding Contribution to the Physician Outreach Program.
- 1988: Abstract Presentation-American Society of Hypertension Annual Meeting, New York, New York. Evaluation of efficacy and safety of Cilazapril versus Inderal LA in patients with essential hypertension.
- 1988-89: Cecil Smith Award for the Most Promising Polo Player, Willow Bend Hunt and Polo Club, Plano, Texas.
- 1989: Outstanding Service and Involvement in the Partnership in Education Program, Metrocrest Chamber of Commerce and Carrollton Farmer's Branch Independent School District and Independent Schools.
- 1989-90: Most Improved Player, Willow Bend Hunt and Polo Club, Plano, Texas.
- 1990-91: Sportsmanship Award, Willow Bend Hunt and Polo Club, Plano, Texas.
- 1991-Present: Reviewer for the Following Journals:

*Journal of Clinical Hypertension, Hypertension, The American Journal of Hypertension, Journal of Human Hypertension, Experimental Hypertension, International Journal of Hypertension, Integrated Blood Pressure Control, Therapeutic Advances in Cardiovascular Disease, Drugs, Expert Review of Cardiovascular Therapy, Journal of Clinical Research and Pharmacoepidemiology, Journal of Geriatric Cardiovascular Medicine, Aging and Drugs, Cardiovascular Expert Review, Journal of Cell Adhesion and Migration, Drugs of Today, Cell Biochemistry and Function, Cardiovascular Diagnosis and Therapy and the Journal of the Renin-Angiotensin Aldosterone System.*

- 1992: "Who's Who Among Rising Young Americans", recognized for achievements in American Society and business.
- 2002: FAA Private Pilots License
- 2004 : FAA Instrument Rating
- 2005 : FAA Multiengine Rating
- 2010-2018: Host, "Su Salud" Radio Show, La Bonita 106.7, Dallas, Texas
- 2011 Academic Editor: International Journal of Hypertension.
- 2015-2018: Board of Directors; Consortium of South East Hypertension Centers.
- 2015-Present:The Open Hypertension Journal; Editorial Board Member.
- 2015-Present:Board of Directors: Inter-American Society of Hypertension
- 2017- Greece Arcadia Sports Hall of Fame Inductee: First US born Professional Soccer player in Argentina
- 2018: Host, "Su Salud" Radio Show, La Nueva 106.5, Dallas, Texas

LICENSURE AND CERTIFICATIONS:

- 12/20/1980: Buenos Aires, Argentina-National Matriculation.
- 01/12/1981: ECFMG Certificate, Dallas, Texas.
- 02/20/1982: Texas Licensure, Federal Licensing Examination.
- 1988: Fellow, American College of Clinical Pharmacology.
- 2009: FAA Designated Aviation Medical Examiner
- 2010: Fellow American Society of Hypertension
- 2014: Civil Air Patrol Health Services Office: Rank of Captain
- 2015: FAA Designated Senior Aviation Medical Examiner

CERTIFICATIONS:

Board Eligible: Clinical Pharmacology

PUBLICATIONS:

- Feldstein CA, Punzi HA: The comparison of hydrochlorothiazide and Hydrochlorothiazide with Metoprolol in patients with essential hypertension during stress testing. *Hispanic-American Journal of Hypertension*, August 1983 (presented at the International Conference on Hypertension, Rio de Janeiro, Brazil, 1981).
- Kaplan NM, Punzi HA: Diabetes and hypertension: guidelines for treatment. *Clinical Diabetes*. 1984; 2:25-35.
- Ram CVS, Punzi HA, Chia BL: Three agents for resistant hypertension: how do they compare? *Modern Medicine* 1984.52 ;(9):88-105.
- McPhaul M, Punzi HA: Sandy A, Borgenelli M, Rude R, Kaplan NM: Snuff induced hypertension in Pheochromocytoma. *JAMA* 1984;252: 2860-2862.
- Punzi HA: Tratamiento de la Hipertension Refractaria. In: Kaplan NM, Feldstein CA (Eds). *TERAPEUTICA CARDIOVASCULAR*. Buenos Aires, Argentina: Panamericana, 128-128, 1986.
- Marculies M, Punzi HA: Voto LS, Hipertension y Embarazo. In: Kaplan NM, Feldstein CA (Eds). *TERAPEUTICA CARDIOVASCULAR*. Buenos Aires, Argentina: Panamericana, 123-128, 1986.
- Feldstein CA, Punzi HA: Drogas Comumente Utilizada en Terapeuticas Cardiovascular. In: Kaplan NM, Feldstein CA, eds. *TERAPEUTICA CARDIOVASCULAR*. Buenos Aires, Argentina: Panamericana, 571-610, 1986.
- Punzi HA, Kaplan NM: Therapy of Hypertension in the diabetic patient: Pharmacologic Intervention. *Cardiovascular Review and Reports*.1987; 8(10):61-63.
- Punzi HA, Kaplan NM: Therapy of Hypertension in the diabetic patient: Non-Pharmacologic Intervention. *Cardiovascular Review and Reports* 1987;8(11):37-40.
- Feldstein CA, Boshini P, Punzi HA: Renovascular Hypertension in a Major University Teaching Hospital. Presented to the Second Inter-University Congress of Internal Medicine in Argentina. Rosario, Argentina, November 29-December 2, 1987.
- Punzi HA, Mills J., Lara S.: Evaluation of efficacy and safety of Cilazapril versus Inderal LA in patients with essential hypertension. *American Journal of Hypertension*. 1988.1(3, 2): 29A.

Punzi HA, Mills JK: Comparison of efficacy, and safety, and tolerability of benazapril to propranolol as add on therapy to hydrochlorothiazide in patients with moderate to severe hypertension. *American Journal of Hypertension*. 1989. Vol 2,5, Part 2, p 512A,.

Punzi HA, Flamenbaum W (series data):CLINICAL CARDIOVASCULAR THERAPEUTICS: HYPERTENSION. Vol. 1, Mount Kisco, New York, Futura Publishing, 1989.

Punzi HA: Hypertension and Concomitant Diseases. In: Punzi HA, Flamenbaum W. (eds.): CLINICAL CARDIOVASCULAR THERAPEUTICS: HYPERTENSION. Vol.1 Mount Kisco, New York, Futura Publishing, pp 247-268, 1989.

Punzi HA, Flamenbaum W: The Future. In: Punzi HA, Flamenbaum W (eds): CLINICAL CARDIOVASCULAR THERAPEUTICS: HYPERTENSION. Vol.1. Mount Kisco, New York, Futura, pp 395-398, 1989.

Punzi HA, Zusman R: Part II, Specific Angiotensin- Converting Enzyme Inhibitors, Captopril. In: Messerli FH (ed.): CARDIOVASCULAR DRUG THERAPY, W.B. Saunders, Philadelphia, Pennsylvania, pp 770-791, July, 1990.

Punzi HA, Mills JK: A Randomized, Double- Blind, Placebo- Controlled parallel Study of the Antihypertensive Response to Three Dose Levels of Celiprolol Hydrochloride and Placebo in Patients with Mild or Moderate Essential Hypertension. *The Journal of Clinical Pharmacology*. 1991;Vol 31, No.9, p. 842,

Punzi HA, Flamenbaum W (series eds): CLINICAL CARDIOVASCULAR THERAPEUTICS: CARDIAC ARRHYTHMIAS: A PRACTICAL APPROACH. Volume 2, Mount Kisco, New York, Futura Publishing, 1991.

Punzi HA, Flamenbaum W (series eds): CLINICAL CARDIOVASCULAR THERAPEUTICS: CORONARY HEART DISEASE AND RISK FACTORS. Volume 3, Mount Kisco, New York, Futurs Publishing, 1991.

Weir MR, Weber MA, Punzi HA: Serfer HM, Rosenblatt S, Cady WJ: A dose escalation trial comparing the combination of diltiazem SR and hydrochlorothiazide with the monotherapies in patients with essential hypertension. *Journal of Human Hypertension*.1992:133-138.

- Punzi HA: Cilazapril versus Propranolol LA in patients with essential hypertension. *Journal of Clinical Research and Pharmacoedemiology*.1992;(6):303-311.
- Punzi HA, Germino FW, Lastara J, Pool P, Spinowitz B, Smith W, Mills D. An open-Label pilot study evaluating the cough profile of fosinopril sodium in hypertensive patients with documented cough associated with previous ace inhibitor monotherapy. *Journal of Hypertension*. 1993;(6,5),
- Germino FW , Lastra J, Pool P, Punzi HA, Spinowitz B, Smith Wm, Wallace S, Willett M, Mills D, De Silva J, Cryer D: Evaluating the Cough Profile of Fosinopril Sodium in Hypertensive Patients with ACE Inhibitor Associated Cough. *Current Therapeutic Research*. 1993;(54.5): 469-475.
- Punzi HA: Safety Update: Focus on Cough. *American Journal of Cardiology*.1993;(72): 1H-4H.
- White WB, Punzi HA, MacIntyre JM, Verburg KM, Anders RJ: Relationship Between Ambulatory and clinic Blood Pressure Measurements in a Large Efficacy study of Verapamil Gastrointestinal Therapeutic System (GITS). *American Journal of Hypertension*. 1994;(7, 4, Part 2):44A.
- Punzi HA, Zusman R: Part II, Specific Angiotensin- Converting Enzyme Inhibitors, Captopril. In: Messerli FH (ed.): CARDIOVASCULAR DRUG THERAPY, second edition W.B. Saunders, Philadelphia, Pennsylvania, pp 726-742, 1996.
- Punzi HA, Novrit BA, and the Trandolapril/Verapamil Multicenter Study Group: Trandolapril in combination with verapamil sr in patients with severe essential hypertension. *American Journal of Hypertension*. 1996; (9, 4, Part 2):143A.
- Punzi HA, Novrit BA, and the Trandolapril/ Verapamil Multicenter Study Group: The treatment of severe hypertension with trandolapril, verapamil, and hydrochlorothiazide. *Journal of Human Hypertension*.1997(11): 477-481.
- Punzi HA, Rhodes MM: Comparison of repeated office blood pressure measurements versus 24 hr. ambulatory blood pressure monitoring. *American Journal of Hypertension*. 1998;(11, No. 4, Part 2):512A.
- Masonson HN, Punzi HA, Neutel JM, et al.: CS-866 (angiotensin II receptor antagonist) a double-blind study using ambulatory blood pressure monitoring in hypertensive patients. *American Journal of Hypertension*.1998;( II, No. 4, Part 2):77A.

- Punzi HA: Why ambulatory blood pressure monitoring? *American Journal of Health-System Pharmacy*. 1998 ;(55 N22 S33):S12-S16
- Punzi HA Noveck R, Weiss RJ et al: Are there difference in the effect of long-acting calcium channel blockers on ambulatory blood pressure? Nisoldipine extended-release versus amlodipine as a model. *Blood Pressure Monitoring*. 1998;(3 N4): 267-272.
- Gradman AH, Gray J, Maggiamo F., Punzi, HA, White WB: Evaluation of the novel angiotensin II antagonist, eprosartan, used once-daily in patients with systemic hypertension. *Clinical Therapeutics*. 1999;(21, N3):442-453.
- Punzi, HA, Punzi CF: Isolated systolic hypertension. In FH Messerli; (Ed) CARDIOVASCULAR CLINICAL CASES. SPECIFIC TREATMENT STRATEGIES. PAN Communications, Surrey, UK. Volume 3. pp.168-173, 2002.
- Punzi HA, Punzi CF: A 13-week, double-blind, placebo-controlled, parallel, multicenter study of eprosartan mesylate given in titrated doses of 600 mg or 1200 mg once daily in patients with isolated systolic hypertension. *American Journal of Hypertension*. 2003;(16, N5 P 2):127A.
- Punzi HA, Punzi CF: Metabolic issues in the antihypertensive and lipid-lowering heart attack trial study. *Current Hypertension Reports* 2004; 6:106-110.
- Punzi HA, Punzi CF for the Eprosartan International Investigators: A 13-week, double-blind, placebo-controlled, parallel, multicenter study of eprosartan mesylate given in titrated doses of 600 mg or 1200 mg once daily in patients with isolated systolic hypertension *Journal of Human Hypertension*. *Journal of Human Hypertension*. 2004;18:655-661.
- Punzi HA, Punzi, CF: An 8-week, double-blind, placebo-controlled, multicenter, ambulatory blood pressure monitoring (ABPM) study of Teveten (eprosartan mesylate) 600 mg and 1200 mg in patients with essential hypertension. *American Journal of Hypertension*. 2005; 18(5 part 2): 93A.
- White WA, Punzi HA, Neutel J, et al. Telmisartan plus hydrochlorothiazide (80/25 mg) has greater antihypertensive effect than valsartan plus hydrochlorothiazide (160/25 mg) in patients with stage 1 and 2 hypertension. 2005 *American Journal of Hypertension*. 18(5 part 2): 97A

- Punzi HA, Punzi CF. A Prospective, Randomized, Open-Label, Blinded Endpoint, Forced-Titration Trial to Compare Tarka (Trandolapril/Verapamil) and Lotrel (Amlodipine/Benazapril) for the Control of Stage I-II Hypertension utilizing Ambulatory Blood Pressure Monitoring. COMPARE Study. 2006 *American Journal of Clinical Hypertension*. 8; 5:A56-A57.
- Punzi HA, Punzi CF. A Prospective, Randomized, Open-Label, Blinded Endpoint, Forced Titration Comparison of Sular (nisoldipine 20 to 40 mg) versus Norvasc (amlodipine 5 to 10 mg) utilizing Ambulatory Blood Pressure Monitoring in patients with Stage I and Stage II Hypertension at 1, 2 and 4 Weeks of Therapy. 2006 *American Journal of Clinical Hypertension*. 8; 5:A56.
- White WA, Punzi HA, Murwin D, et al. Effects of the Angiotensin II Receptor Blockers Telmisartan vs Valsartan in Combination with Hydrochlorothiazide 25 mg Once Daily for the Treatment of Hypertension 2006 *The Journal of Clinical Hypertension*. Vol 8:No 9. 626-633.
- Kereiakes D, Neutel J, Punzi HA, et al. Comparative blood pressure lowering efficacy of Olmesartam/hydrochlorothiazide and benazepril/amlodipine in patients with Stage 2 hypertension. 2007 *The Journal of Clinical Hypertension*. Suppl A Vol. 9 No 5. A168
- Neutel J, Kereiakes D, Punzi, H, et al. What is the optimal combination therapy for Hypertension: Rationale and design of a study comparing Benazepril/amlodipine with olmesartan medoxomil/hydrochlorothiazide. 2007 *The Journal of Clinical Hypertension*. Sup A Vol. 9 No 5. A172-A173.
- Neutel J, Kereiakes D, Punzi H, et al. Attainment of blood pressure goals in patients with Stage 2 hypertension treated with olmasartan/hydrochlorothiazide or Benazepril/amlodipine. 2007 *The Journal of Clinical Hypertension*. Sup A Vol 9 No 5. A173.
- Punzi H, Kereiakes D, Neutel J, et al. Effect of olmesartan and benazepril on plasma renin Activity in patients with stage 2 hypertension. 2007 *The Journal of Clinical Hypertension* Sup A Vol. 9 No 5. A168

Kereiakes D, Neutel J, Punzi HA, et al. "Efficacy and Safety of Olmesartan Medoxomil and Hydrochlorothiazide Compared with Benazepril and Amlodipine Besylate". *Am J Cardiovasc Drugs* 2007; 7 (5): 361-372

Punzi HA, Kereiakes D, Xu J, et al. Blood pressure lowering efficacy of olmesartan medoxomil/HCTZ and benazepril/amlodipine in patients stratified by age and gender. 2008 *Journal of Clinical Hypertension* Suppl A, Vol 10 No 5. A32

Neutel J, Punzi, HA, Xu J, et al. Blood pressure lowering efficacy of olmesartan medoxomil/HCTZ versus benazepril/amlodipine therapy in black and non-black patients with stage 2 hypertension. 2008 *Journal of Clinical Hypertension* Suppl A, Vol 10 No 5. A28.

Neutel JM, Germino WF, Punzi, HA, McBride M, Bryson C, Belder R: Results of a double blind placebo controlled study to evaluate the efficacy and safety of PS 433540 in human subjects with hypertension. 2008. *Circulation*:118S.886.

Punzi HA. Efficacy and safety of olmesartan medoxomil alone and in combination with hydrochlorothiazide. *Expert Review of Cardiovascular Therapy* 2009, Vol. 7, No. 3, Pages 229-239

Kawata AK, Revicki DA, Thakkar R, Jiang P, Krause S, Davidson MH, Punzi HA, Padley RJ Flushing Assessment Tool (FAST<sup>®</sup>): psychometric properties of a new measure assessing flushing symptoms and clinical impact of niacin therapy. *Clin Drug Invest* 2009; 29(4): 215-229.

Littlejohn T, Graff A, Majul CR, Punzi H, Oigman W, Olvera R, Kobe M, Seeber M. Efficacy of telmisartan in combination with amlodipine in hypertensive patients from Latin and North America: Sub-analysis from a factorial design study. *Journal of Clinical Hypertension* 2009, Suppl A Vol 11 No 4. A36

Littlejohn T, Punzi H, Webster D, Majul CR, Oigman W, Olvera R, Seeber M, Kobe M, Schumaker H. Telmisartan plus amlodipine combination is effective in both treatment-naïve and previously treated hypertensive patients: Sub-analysis from a factorial design study. *Journal of Clinical Hypertension* 2009, Suppl A Vol 11 No 4. A37

Littlejohn T, Graff A, Punzi H, Majul CR, Oigman w, Olvera R, Seeber M, Kobe M, Schunaker H. Efficacy of telmisartan in combination with amlodipine in hypertensive patients according to race: Sub-analysis from a factorial design. *Journal of Clinical Hypertension* 2009, Suppl A Vol 11 No 4. A37

Neutel J, Kereiakes DJ, Punzi H, Shojaee A, Waverczak WF, Dubiel R, Xu J. Efficacy and safety of an amlodipine/olmesartan medoxomil based titration regimen on blood pressure assessed by means 24hour ambulatory blood pressure monitoring (ABPM) in patients with hypertension. *Journal of Clinical Hypertension* 2009, Suppl A Vol 11 No 4. A129

Neutel J, Punzi H, Shojaee A, Waverczak WF, Dubiel R, Xu J. Efficacy of an amlodipine olmesartan medoxomil titration regimen: Analysis by baseline hypertension stage. *Journal of Clinical Hypertension* 2009, Suppl A Vol 11 No 4. A130

Punzi H, Lewin A, Shojaee A, Waverczak Wf, Dubiel R, Xu J. Efficacy of an amlodipine olmesartan medoxomil based titration regimen on blood pressure goal achievement in patients with hypertension. *Journal of Clinical Hypertension* 2009, Suppl A Vol 11 No 4. A133

Punzi H, Lewin A, Littlejohn T, Shojaee A, Waverczak WF, Dubiel R, Xu J. Efficacy of an amlodipine olmesartan medoxomil based titration regimen in patients with or without diabetes and hypertension. *Journal of Clinical Hypertension* 2009 , Suppl A Vol 11 No 4. A134

Punzi H, Kereiakes DJ, Shojaee A, Waverczak WF, Roberts D, Xu J. Efficacy of an amlodipine/olmesartan medoxomil-based titration regimen in patients with hypertension: Analysis by age and gender. *Journal of Clinical Hypertension* 2009, Suppl A Vol 11 No 4. A134

Punzi HA, Punzi CF. Pilot study to evaluate a novel water displacement technique to differentiate the effects of two dihydropyridine calcium antagonist on lower extremity edema. *Journal of Clinical Hypertension* 2009, Suppl A Vol 11 No 4. A135

Punzi HA, Neutel JM, Kereiakes DJ, et.al. Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: The AZOR trial evaluating blood pressure reductions and control (AZTEC) study. *Therapeutic Advances in Cardiovascular Disease* 2010, 4 [4] 209-221.

Punzi HA, Lewin A, Lukic T, et.al. Efficacy and safety of nebivolol in Hispanics with stage I-II hypertension: a randomized placebo-controlled trial. *Therapeutic Advances in Cardiovascular Disease* 2010, 4 [6] 349-357.

Weir MR, Punzi, HA, Flack J, et.al. A randomized, double-blind, forced titration study to compare olmesartan medoxomil versus losartan potassium in patients with stage 1 and 2 hypertension. *Postgraduate Medicine* 2011. 123 [1] 80-87.

Punzi HA. Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination. *Integrated Blood Pressure Control* 2011;4 73-83.

Punzi HA, Shoajee A, Waverczak WF, Maa JF. Efficacy of amlodipine and olmesartan medoxomil in hypertensive patients with diabetes and obesity. *The Journal of Clinical Hypertension*. 2011. 13 (6). 422-430.

Papademetriou V, Tsioufis C, Gradman A, Punzi HA. Difficult-to-Treat or Resistant Hypertension: Etiology, Pathophysiology, and Innovative Therapies. *International Journal of Hypertension*. 2011. Volume 2011. Pages 1-4.

Punzi HA, Punzi CF: Dual therapy of nebivolol/amlodipine versus metoprolol/amlodipine in subjects with hypertension and pedal edema. *Journal of Clinical Hypertension* 2012. 14 suppl 1. A65.

Punzi HA, Lewin A, Wei LJ, Chavanu KJ: Efficacy/safety of olmesartan medoxomil versus losartan potassium in naive versus previously treated subjects with hypertension. *Advances In Therapy*. 2012. 29 (6) 524-537.

Punzi HA, Shojaee A, Maa JF: Efficacy and tolerability of fixed-dose amlodipine/olmesartan medoxomil with or without hydrochlorothiazide in Hispanic and non-Hispanic patients whose blood pressure is uncontrolled on antihypertensive monotherapy. *Therapeutic Advances in Cardiovascular Disease* 2012 6 (4) 149-161.

Punzi HA, Dahlof B, Webster D, et al; The effects of telmisartan and amlodipine in treatment-naive and previously treated hypertensive patients: A subanalysis from a 4X4 factorial design study. *Clinical and Experimental Hypertension*. 2012

Lewin A, Punzi HA, Luo X, Stapff, M: Nebivolol is an Efficacious and Well Tolerated Therapy for Individuals with Systolic Stage II Hypertension: Results of a Randomized, Placebo-Controlled Trial *Clinical Therapeutics*. 2013.

Punzi HA, Punzi CF. The use of fixed dose triple drug therapy, olmesartan, amlodipine and HCTZ as replacement therapy for patients not at goal blood pressure. *The Journal of Clinical Hypertension*. 2013 15(1) A57.

Ferrario CM, Punzi HA, Moore MA. ARBs in Hypertension. Focus on Olmesartan. MacMillan Medical Communications 2013

Ferrario CN, Punzi HA, Panjabi S, Jessup JA. OLMESARTAN IN HYPERTENSION. Physician Quick Reference Series. MacMillan Medical Communications. 2013

H Punzi. Efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide in patients with hypertension not at goal with mono, dual or triple drug therapy: results of the CHAMPiON study. *Ther Adv Cardiovasc Dis* 2014, Vol. 8(1) 12–21

Neutel J, Giles TD, Punzi, HA, et.al. Long-Term Safety of nebivolol and valsartan combination therapy in patients with hypertension: an open-label, single-arm , multicenter study. *Journal of the American Society of Hypertension* 2014 8(12) 915-920.

Varagic J, Punzi H, Ferrario CM. Clinical utility of fixed-dose combinations in hypertension: evidence for the potential of nebivolol/valsartan. *Integrated Blood Pressure Control* 2014. 7. 61-70.

Punzi HA. A randomized, open-label, blinded-endpoint, active-comparator, forced-titration study to compare nebivolol versus metoprolol as dual therapy with amlodipine in patients with hypertension: results of the tandem study. *Journal of the American Society of Hypertension* 2014. 8(4):e27

Punzi HA. Combination therapy with nebivolol/amlodipine is superior to metoprolol/amlodipine in the control of cuff and 24-hr ambulatory blood pressure. *Journal American Society of Hypertension*. 2015 9(4S) e24.

The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. *N Engl J Med*. 2015; 373:2103-2116.

Giles TD, Punzi H, Mallick M, Ferguson W, Patel M. Increased placebo response in Hispanics vs non-Hispanics in nebivolol hypertension trials: A post-hoc pooled analysis. *Journal American Society of Hypertension*. 2016 10(4S) e62-e63.

Ishak, J., Rael, M., Punzi, H. et al. Additivity of Nebivolol/Valsartan Single-Pill Combination Versus Other Single-Pill Combinations for Hypertension. 2016, *J Am Soc Hypertens*.10 Suppl 1:e5-e6

Rodriguez CJ, Still CH, Garcia KR, Wagenknecht L, White S, Bates JT, Del Cid MV, Lioudis M, Barrera NL, Moreyra A, Punzi H, Ringer RJ, Cushman WC, Contreras G, Servilla K, Rocco M. Baseline blood pressure control in Hispanics: characteristics of Hispanics in the Systolic blood pressure intervention trial. *J Clin Hypertens* 2016; 1-10

Ishak J, Rael M, Punzi H, Gradman A, Anderson L, Patel M, Ali S, Ferguson W, Neutel J. ADDITIVITY OF NEBIVOLOL/VALSARTAN SINGLE-PILL COMBINATIONS VERSUS OTHER SINGLE-PILL COMBINATIONS FOR HYPERTENSION" *J Clin Hypertens* 2018;20:143-149

Basile J, Egan B, Punzi H, Ali S, Li Q, Patel M, Neutel J. [Risk of Hospitalization for Cardiovascular Events with  \$\beta\$ -Blockers in Hypertensive Patients: A Retrospective Cohort Study.](#) *Cardiol Ther.* 2018 Sep 6. doi: 10.1007/s40119-018-0117

Alexander L. Bullen<sup>1</sup>, Ronit Katz<sup>2</sup>, Alexandra K. Lee<sup>3</sup>, Cheryl A.M. Anderson<sup>1,4</sup>, Alfred K. Cheung<sup>5,6</sup>, Pranav S. Garimella<sup>1</sup>, Vasantha Jotwani<sup>7,8</sup>, William E. Haley<sup>9</sup>, Areef Ishani<sup>10</sup>, James P. Lash<sup>11</sup>, Javier A. Neyra<sup>12,13</sup>, Henry Punzi<sup>14</sup>, Anjay Rastogi<sup>15</sup>, Erik Riessen<sup>6</sup>, Rakesh Malhotra<sup>1</sup>, Chirag R. Parikh<sup>16</sup>, Michael V. Rocco<sup>17</sup>, Barry M. Wall<sup>18</sup>, Udayan Y. Bhatt<sup>19</sup>, Michael G. Shlipak<sup>3,7</sup>, Joachim H. Ix<sup>1,20</sup>, Michelle M. Estrella<sup>3,7</sup>  
Markers of Kidney Tubule Cell Function and Injury and Risk of Subsequent Acute Kidney Injury: The SPRINT Trial. *Kidney International.* 2019. 96(2):470–479 .

Garimella PS, Lee AK, Ambrosius WT, Bhatt, U, Cheung AK, Chonchol M, Craven T, Hawfield AT, Jotwani V, Killeen A, Punzi H, Sarnak MJ, Wall BM, Ix JH and Shlipak MG. Markers of Kidney Tubule Function and Risk of Cardiovascular Disease Events and Mortality in the SPRINT Trial. *Eur H Journal.* June 2019.

Nasrallah I, Detre J, Punzi H et.al. Effects of Intensive Blood Pressure Control on Cerebral Blood Flow and Vascular Reactivity in SPRINT 2019 in Press

Jovanovich A, Ix J, Punzi H et.al. Falls and Frailty in SPRINT 2019 in Press

Ginsberg C Ix J, Punzi H et.al. The Effects of Intensive Blood Pressure Control on Markers of Mineral Metabolism in SPRINT 2019 in Press

Zhang W, Ix J, Punzi H et.al. Association of Serum Creatinine Elevations during Follow-up with Subsequent Cardiovascular Disease Events and All-Cause Mortality in SPRINT 2019 in Press

Malhotra R, Katz R, Jotwani V, Ambrosius WT, Raphael KL, Haley W, Rastogi A, Cheung AK, Freedman BI, Punzi H, Rocco MV, Ix JH\*, Shlipak MG\*. Urine Markers of Kidney Tubule Cell Injury and Kidney Function Decline in SPRINT Trial Participants with CKD. *Clin J Am Soc Nephrol.*, 2019; In Press.

Punzi HA. *The ABCD of Hypertension Book.* Krager Publishing. In Press 2019

### **Clinical Research Trials Completed as Principal Investigator**

Evaluation of Efficacy and Safety of Cilazapril (Inhibace) versus Inderal LA (Propranolol HCL) in Patients with Essential Hypertension. Protocol No.: N2963A Date: April 2, 1986

Evaluation of Efficacy and Safety of Cilazapril (Inhibace) in combination with Hydrochlorothiazide in Patients with Essential Hypertension. Protocol No.:N3054A Date: September, 1986

Evaluation of Antihypertensive effect of once daily Ramipril Therapy vs. once daily Enalapril Therapy using non-invasive 24-hr Blood Pressure Recording System. Protocol No.: 354 Date: December 4, 1986

A Multicenter, Parallel Study to compare the Efficacy, Safety and Tolerability of CGS 14824A to Propranolol as add on Therapy to Hydrochlorothiazide in Patients with Moderate to Severe Hypertension during a 10-week Double-Blind Treatment Period. Protocol: GHBA-87 Date: April 10, 1987

Captopril vs Hydrochlorothiazide: A Comparison of Effects on Quality of Life. Squibb & Sons Pharmaceuticals Protocol No.: 12928-245 Date: June 30, 1987

A Randomized, Double-Blind, Placebo-Controlled Parallel Study of the Hypertension Response of Patients with Mild to Moderate Essential Hypertension t Three Dose Levels of Celiprolol Hydrochloride and Placebo. Protocol: RG 5320A-107 Date: August 7, 1987

Evaluation of RS-10085-197, an Ace Inhibitor, in Long-term Treatment of Hypertension Patients not previously treated with RS-10085-197. Protocol No.: Syntex Study ICM 1534 Date: November 13, 1987

Double-Blind, Placebo-Controlled, Four-way Parallel Dose-Ranging Study to Evaluate the Safety and Efficacy of Oral Gallopamil-SR Therapy (100,150, and 200mg/day) in Patients with Mild to Moderate Essential Hypertension. Knoll Pharmaceuticals Protocol No.: G-21-HTN Date: March, 1988

Open-Label Study of the Long-Term Safety of Oral Gallopamil-SR as Treatment for Mild to Moderate Essential Hypertension. Knoll Pharmaceuticals Protocol No.: G-30-HTN Date: March, 1988

Dose Evaluation of Diltiazem SR/Hydrochlorothiazide in Combination vs Single Agents and Placebo. Protocol No.: DZPROO43 Date: February 24, 1988

The Safety and Efficacy of Cardizem SR in Patients with Mild to Moderate Hypertension. Protocol No.: DZPR-0054 Date: April 22, 1988

Once Daily Captopril Modified Release Capsules for the Treatment of Mild-to-Moderate Essential Hypertension. Protocol No.: 12,928-296 Date: August 22, 1988

Parallel Comparison of Three Doses of Peridopril tert-Butylalmine and Placebo in Patients with Mild to Moderate Hypertension. Protocol No.: PH Phase III Date: October 17, 1988

Parallel Comparison of Four Doses of Perindopril tert-Butylamine and Placebo in Patients with Mild to Moderate Hypertension. Protocol No.: PB Date: November 14, 1988

Placebo- Controlled Trial of Various Doses of Zofenopril Administered twice daily in Mild to Moderate Hypertension. Protocol No.: 21,974-58 Date: August 11, 1989

Double-Blind Parallel Efficacy and Safety Study of Various Doses RS-43285-193 Ranolazine vs. Placebo in Patients with Chronic Stable Angina Pectoris. Syntex Labs Protocol No.: Syntex Study ICM 1513 Date: April 19, 1989

Multicenter, Placebo Controlled Study Evaluating the Dose Response of Cilazapril (Inhibace) at Higher Doses. Protocol No.: Cilazapril N3432B Date: April 12, 1989

A Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Antihypertensive Safety and Efficacy Study of Once-Daily Diltiazem HCL SR Administered Alone and Concomitantly with Indapamide. Protocol No.: RG-83606-105 Date: August 1, 1989

A Randomized, Double-Blind, Placebo Controlled Trial to Determine the Safety and Efficacy of Sustained Release Diltiazem (C-84 Capsules) in Patients with Stable Angina Pectoris at Four Dosage Levels: 60mg bid, 90mg bid, 180mg bid, and 240mg bid. Protocol No.: 12485 Date: December 8, 1989

Effect of Fosinopril Compared to Verapamil SR on the Quality of Life and Hemodynamics in Elderly Hypertensive Male Patients. Protocol No.: 23103-80 Date: August 20, 1990

An Open-Label Assessment of the Safety and Efficacy of Isradipine in the Treatment of Patients with Mild to Moderate Hypertension. Protocol No.: PNH-408 Date: November 16, 1989

A Double-Blind Placebo Controlled Comparative Study of the Safety and Efficacy of Nifedipine Sustained-Release (SR) Tablets Titrated from 20mg to 100mg daily vs Verapamil SR Tablets Titrated from 240mg to 480mg daily in Patients with Mild to Moderate Hypertension. Protocol No.: D89-023 Date: October 20, 1989

Double-Blind Randomized Study of the Safety and Efficacy of Once Daily Doses of Nisoldipine 20,40 and 60mg (x30mg) Core-Coat Tablets vs Placebo in Combination with Atenolol 50mg in Hypertensive Patients. Protocol No.: D89-029 Date: March 2, 1990

Double-Blind, Randomized, Three-way Parallel Group Study to Evaluate the Safety and Efficacy of Oral Anipamil compared to Oral Isoptin SR Therapy and Placebo in Patients with Mild to Moderate Essential Hypertension. Protocol No.: AN-21-HTN Date: March, 1990

A Randomized, Double-Blind, Multicenter, Parallel Study to compare the Duration of the Antihypertensive Effect and Safety of Four Dose Level of Benidipine (KW-3049) with that of Placebo in Patients with Mild to Moderate Uncomplicated Essential Hypertension. Protocol No.: GHBA-340 Date: February 27, 1990

The Effect of Food on the Efficacy of Celiprolol Hydrochloride in Mild and Moderate Essential Hypertensive Patients. Protocol No.: RG 5320A-118 Date: March 1, 1990

Evaluation of the Safety and Efficacy of Oral Trandolapril in Combination with Verapamil (Isoptin SR) in Patients with Severe Essential Hypertension. Protocol No.: TV-40-HTN Date: January 4, 1991

An Open-Label Multicenter Study to Evaluate the Safety and Efficacy of the Substitution of Adalat SR Tablets for Calan SR Caplets in the Treatment of Mild Hypertension. Protocol No.: D90-042 Date: February 7, 1991

An Open-Label Pilot Study Evaluating the Cough Profile of Fosinopril Sodium in Hypertensive Patients with Cough Associated with Ace Inhibitor Monotherapy. Protocol No.: CV 119-127 Date: May 20, 1992

A Double-Blind, Randomized, Parallel Group Comparative Study of the Safety and Efficacy of Nifedipine Coat-Core (30mg and 60mg daily) versus Nifedipine Gits (30mg and 60mg daily) administered without food in Patients with Mild to Moderate Hypertension. Protocol No.: D93-032 Date: October 27, 1993

An 8-Week, Double-Blind, Parallel, Dose Range, Multicenter, North American Comparison of Oral SK & F 108566 25 to 400mg twice daily with Placebo in Patients with Essential Hypertension (DBP >95 and <114 mmHg). Protocol No.: SK & F 108566 Date: July 15, 1994

A Randomized, Double-Blind, Placebo-Controlled, Dose Response Trial of BIBR 277 SE in Patients with Mild to Moderate Hypertension. Protocol No.: 502.203  
Date: September 21, 1994

Randomized, Double-Blind, Multicenter Dose-Ranging Trial of once daily BAY 10-6734 vs Placebo vs Lisinopril in Essential Hypertension. Protocol No.: D94-017  
Date: February 27, 1995

Trandolapril in Hypertension: Effectiveness when added to Verapamil SR. Protocol No.: TV-48-HTN Date: May 15, 1995

Clinical Protocol for a Randomized, Multicenter, Double-Blind Study Comparing PPR Verapamil to Nifedipine-Gits (Procardia XL) in the Treatment of Hypertension, IND # 39,459. Protocol No.: N26-94-02-005 Date: July 18, 1995

A Randomized , Double-Blind, Placebo-Controlled, Dose-Ranging Study of CS-866 using Ambulatory Blood Pressure Monitoring in Hypertensive Patients. Protocol No.: 866-204 Date: December 15, 1995

A 54 Week Open-Label Assessment of the Safety and Efficacy Profile of Atorvastatin as Compared to Simvastatin when used to Optimally Control Patients with Mixed Dyslipidemia.  
Protocol No.: 981-158 Date: December 20 1996

A Randomized Double-Blind Placed-Controlled Multicenter Study Measuring the Effects of Glyburide with the Addition of Troglitazone on Achieving Glycemic Control in Type II (Non-Insulin-Dependent) Diabetes Mellitus (NIDDM) Patients.  
Protocol No.: 991-085 Date: November 11, 1996

A Randomized, Placebo-Controlled, Parallel-Group Study of CS-866 with Long-Term Safety Evaluation in Patients with Essential Hypertension.  
Protocol No.: 866-305 Date: June 26, 1997

A Randomized, Placebo-Controlled, Dose-Titration Study of CS-866 with Long-Term Safety Evaluation in Patients with Essential Hypertension.  
Protocol No.: 866-306 Date: June 27, 1997

Placebo Controlled Study of SR Moxonidine in Stage 1 and Stage 2 Hypertension.  
Protocol No.: B3N-MC-EUAT Date: December 12, 1997

A Prospective, Multinational, Multicenter, Double-Blind, Randomized, Active-Controlled Trial in Patients with Essential Hypertension to compare the Effect of Valsartan 80 and 160mg, with or without the addition of Hydrochlorothiazide, once daily to that of Amlodipine 5 and 10mg once daily, with or without the addition of Hydrochlorothiazide, on Cardiovascular Morbidity and Mortality.  
Protocol No.: 405 Date: April 17, 1998

A 13-Week, Double-blind, Placebo-controlled, Parallel, Multicenter Study of Teveten given in Titrated Doses of 600mg or 1200mg once daily, in Patients with Isolated Systolic Hypertension (Sit SBP > 160mmHg and Sit DBP < 90mmHG).  
Protocol No.: 145 Date: September 11, 1998

A multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Study of Lercanidipine Hydrochloride in Patients with Essential Hypertension.  
Protocol No.: REC 15/2375-CPL2- 0002 Date: August 10, 1998

Clinical Protocol for Comparative Study of Covera-HS (Coer-Verapamil) vs. an Ace Inhibitor (Enalapril), and Angiotensin II Receptor Blocker (Losartan, and Placebo in Patients with Stage I-III Essential Hypertension, Ind#39,459  
Protocol No.: N26-98-02-014 Date: June 5, 1998

A Randomized, Double-Blind, Active-Controlled Evaluation of the AntiHypertensive Response to Omapatrilat in Subjects Uncontrolled on Calcium-Channel Blocker Therapy.  
Protocol No.: CV 137-072 Date: July 06, 1999

A Prospective, Randomized, Double-Blind, Double-Dummy, Titration-to-Response Trial comparing Micardis (Telmisartan)(40 & 80mg QD) and Cozaar (Losartan (50 & 100mg QD) in Patients with Mild-to-Moderate Hypertension using Ambulatory Blood Pressure Monitoring.  
Protocol No.: 502.343 Date: December 10, 1999

Clinical Protocol to Evaluate the Effects of Twice Daily Celecoxib versus Placebo on Blood Pressure in Hypertensive Patients whose Blood Pressure is Controlled with the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, Ind #48,395  
Protocol No.: N49-99-02-048 Date: November 30, 1999

Protocol for the Collection of Blood Specimens for the Evaluation of Platelet GP Iib/IIIa Receptor Occupancy of Lotrafiban.  
Protocol No.: SB 214857/030 (Bravo) Date: March 2, 1999

A Prospective, Randomized, Open-Label, Blinded –Endpoint (Probe) Design, Parallel Study Comparing the Efficacy of the Combination of Irbesartan Plus Lisinopril, to Lisinopril and to Irbesartan in Subjects with Mild to Moderate Hypertension.  
Protocol No.: BMS 001 Date: August 14, 2000

A Double-Blind, Randomized, Parallel Group, Dose Response, Multi-Center Study to Compare the Safety and Efficacy of Diltiazem HCL Extended Release Capsules (G99) to Placebo Dosed at Bedtime and to G99 Dosed in the Morning in Patients with Essential Hypertension.

Protocol No.: B00.CT3.011.Dil G99 Date: May 9, 2000

A Double-Blind, Randomized, Parallel Group, Dose Response, Multi-Center Study of the Safety and Efficacy of Diltiazem HCL Extended Release Capsules (G99) compared to Placebo Dosed at Bedtime and to G99 Dosed in the morning, in the Treatment of Chronic, Stable, Exercise-Induced Angina.

Protocol No.: B00.CT3.012.Dil G99 Date: September 8, 2000

A Multi-centre Study to Examine the Value of Natriuretic Peptides in the Assessment of Asymptomatic Left Ventricular Dysfunction in a Population at High Risk of Developing Congestive Heart Failure.

Protocol No.: 217242/082 Date: February 17, 2000

A Prospective, Open-Label, Single Arm, Forced Titration, Multicenter Study to Assess the Effect of Valsartan (80mg or 160mg) on Heart Rate Variability (HRV) in Patients with Chronic Congestive Heart Failure.

Protocol No.: CVAL489 US12 Date: August 25, 2000

Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Protocol ALLHAT Date April 2000

A Placebo-Controlled Trial of Bidil Added to Standard Therapy in African-American Patients with Heart Failure.

Protocol No.: NDA 20-727 Date: October 22, 2001

Efficacy and Safety Study of the Oral Direct Thrombin Inhibitor H 376/95 compared with Dose-Adjusted Warfarin (Coumadin) in the Prevention of Stroke and Systemic Embolic Events in Patients with Atrial Fibrillation.

Protocol No.: 233 (SH-TPA-0005) Date: October 31, 2001

Systolic and Pulse Pressure Hemodynamic Improvement by Restoring Elasticity: The Sapphire Study.

Protocol No.: ALT-711-0107 Date: December 18, 2001

A Double-Blind, Randomized, Placebo and Active Controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy and Safety of once daily Oral Administration of 5mg, 10mg, 25mg, and 50mg of M100240 for 8 weeks in Subjects with Mild to Moderate Essential Hypertension.

Protocol No.: M100240/2004 Date: June 8, 2001

A Randomized, Placebo-Controlled, Multicenter, Fixed Dose Study to compare the Blood Pressure Response of Patients with Moderate Hypertension Receiving Lercanidipine 10mg, 20mg, 40mg, or Placebo.  
Protocol No.: LER-MD-001 Date: May 15, 2001

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vitacor Plus and Relacor in Adult Patients with Mild (Stage I) Essential Hypertension.  
Protocol No.: MRI-01-001 Date: June 26, 2001

A multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the effect of a continuous-combined HRT Preparation containing 1mg Estradiol and 3mg Drospirenone on Blood Pressure in Mildly Hypertensive Postmenopausal women.  
Protocol No.: 305140 Date: April 17, 2001

A Prospective, Randomized, Double-Blind, Force Titration Trial to compare the Efficacy of Micardis (Telmisartan 80mg p.o. once daily) and Diovan (Valsartan 160mg p.o. once daily) using ambulatory Blood Pressure Monitoring (ABPM) in Patients with Mild-to-Moderate Hypertension after missing one dose.  
Protocol No.: 502.327 Date: June 5, 2002

A Multicenter Prospective, Randomized, Double-Blinded, Parallel Group Study comparing the Effects of Lotrel (5/20mg) to Amlodipine (5mg) and Benazepril (20mg) on Systolic Blood Pressure and Pulse Pressure in Patients with Systolic Hypertension.  
Protocol No.: CCIB002FUS08 Date: May 16, 2002

A Prospective, randomized, open-label, blinded end-point, forced-titration trial to compare Micardis Plus/ Micardis HCT (Telmisartan combined with Hydrochlorothiazide 80mg/12.5mg) to Diovan HCT (Valsartan combined with Hydrochlorothiazide 160mg/12.5mg), for the control of mild-to-moderate hypertension in obese Patients with Type-2 Diabetes Mellitus using Ambulatory Blood Pressure Monitoring.  
Protocol No.: 502.399 Date: November 4, 2002

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled and Open-Label Evaluation of the Safety and Efficacy of Dual Therapy with Atorvastatin Plus Amlodipine when compared to either Therapy Alone in the Treatment of Patients with Simultaneous Hyperlipidemia and Hypertension (The Avalon Study).  
Protocol No.: A3841001 Date: July 30, 2002

Expect-EXPerience with Eprosartan Clinical Trial an Open-Label Multicenter Pilot Study in Patients with Mild to Moderate Hypertension.  
Protocol No.: 03BVL001 Date: June 6, 2003

A Phase 3b, Randomized, Open-Label, Active-Controlled Study to Compare the Effects of Tarka and Lotrel on Albuminuria in Hypertensive, Type 2 Diabetic Subjects with Diabetic Nephropathy.

Protocol No.: M03-599 Date: December 10, 2003

Identification of Genetic Markers (Gene Sequence Variation[s] Responsible for or Predictive for Occurrence of Angioedema in Subjects Treated with ACE Inhibitors and/or ACE-NEP Inhibitors.

Protocol No.: AVE7688A/1099 Date: October 06, 2003

Clinical Protocol for a 12 Week Randomized, Double-Blind, Placebo Controlled Multicenter Study of the Analgesic Efficacy of Celecoxib 200mg QD and 200mg BID compared to Placebo in Patients with Chronic Low Back Pain.

Protocol No.: Coxa-0508-269 Date: April 25, 2003

A Randomised, Double-Blind, Double-dummy, Placebo-Controlled, Forced-Titration, comparison of Micardis HCT ( Telmisartan 80mg/Hydrochlorothiazide 25mg) versus Diovan HCT (Valsartan 160mg/Hydrochlorothiazide 25mg) using seated trough cuff Blood Pressure in Patients with Stage I and Stage 2 Hypertension.

Protocol No.: 502.421 Date: June 20, 2003

A Randomized, Double-Blind, Placebo Controlled, Multicenter, Phase III Study of Rosuvastatin (Crestor) 20mg in the Primary Prevention of Cardiovascular Events among Subjects with Low Levels of LDL-Cholesterol and Elevated Levels of C-Reactive Protein.

Protocol No.: 4522US/0011 Date: October 21, 2004

Compare the Time of Onset of Blood Pressure Control of Sular and Norvasc at one, two, and four weeks of Treatment.

Protocol No.: P45 FH001 Date: April 21, 2004

A Prospective, Randomized, open-Label, Blinded Endpoint, Forced-Titration Trial to compare Tarka (Trandolapril/Verapamil) and Lotrel (Amlodipine/Benazepril) for the control of Stage I-II Hypertension utilizing Ambulatory Blood Pressure Monitoring.

Protocol No.: P45 A001 Date: June 21, 2004

A Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Phase IV Study Comparing Telmisartan 80mg and Hydrochlorothiazide 25mg versus Valsartan 160mg and Hydrochlorothiazide 25mg taken orally for with weeks in Patients with Stage 1 or Stage 2 Hypertension.

Protocol No.: 502.476 Date: April 8, 2005

A Randomized, Double-blind, Double-dummy, Placebo-controlled, 4x4 Factorial Design Trial to evaluate Telmisartan 20,40, and 80 mg tablets in combination with Amlodipine 2.5, 5 and 10 mg capsules after eight weeks of Treatment in Patients with Stage I or II Hypertension, with ABPM Sub-study.

Protocol No.: 1235.1 Date: September 28, 2005

A Phase 2 Multicenter Randomized Double-Blind Placebo Controlled Dose Ranging Study of TBC 3711 in Subjects with Resistant Hypertension.  
Date: December 22, 2005

A Study on the Efficacy and Safety of Olmesartan Medoxomil and its combination with Hydrochlorothiazide compared with an Ace Inhibitor and its Combination with a Calcium Channel Blocker in Patients with Stage 2 Hypertension.  
Protocol No.: 866-447 Date: March 8, 2006

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study of the Effects of 6R-BH4 on Blood Pressure in Subjects with Poorly Controlled Systemic Hypertension.  
Protocol No.: HTN-001 Date: March 17, 2006

A Randomized, Double-Blind, Multicenter, Parallel Study Evaluating the Efficacy and Safety of a Combination of Ramipril Plus Hydrochlorothiazide versus the Component Monotherapies in Subjects with Essential Hypertension.  
Protocol No.: K749-06-3001 Date: June 16, 2006

A Long-Term, Open-Label, Safety Extension Study of the Combination of Fenofibric Acid and Statin Therapy for Subjects with Mixed Dyslipidemia.  
Protocol No.: M05-758 Date: July 26, 2006

A Phase 2, Multicenter, Randomized, double-Blind, Placebo Controlled, Parallel Study of the Effects of GR-BH4 on Blood Pressure in Subjects with Poorly Controlled Systemic Hypertension.  
Protocol No.: HTN-001 Date: August 31, 2006

A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of Fenofibric Acid and Atorvastatin Calcium Combination Therapy to Fenofibric Acid and Atorvastatin Calcium Monotherapy in Subjects with Mixed Dyslipidemia.  
Protocol No.: M05-750 Date: November 20, 2006

A Randomized Double-Blind, Double Dummy, Placebo Controlled, 4x4 Factorial Design Treatment to Evaluate Telmisartan 20, 40, and 80mg Tablets in Combination with Amlodipine 2.5, 5, and 10mg with Stage 1 or 2 Hypertension with an ABPM Substudy.  
Protocol No.: 1236.1 Date: November 29, 2006

A Prospective, Open Label Study to Assess the Efficacy and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Subjects with Stage 1 and Stage 2 Hypertension.

Protocol No.: 8663-402 Date: September 26, 2007

Metabolic Effects of Nebivolol Compared to Metoprolol ER in Hypertensive Patients with Impaired Glucose Tolerance or Impaired Fasting Glucose

Protocol: NEB-MD-04 Date: November 29, 2007

A Prospective, Randomized, Double-Blind Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of a Novel Dual Angiotensin (AT) and Endothelin (Eta) Receptor Antagonist (PS433540) in Subjects with Stage 1 and Stage 2 Hypertension.

Protocol No.: PCO-C-008 Date: December 30, 2007

A Randomized, Double-Blind, Parallel Multicenter Placebo-Controlled Prospective Study to Evaluate the Functionality of the Flushing Assessment Tool (FAST) in Subjects Administered Niaspan Plus Acetylsalicylic Acid (ASA), Niaspan Plus ASA Placebo or Niaspan Placebo Plus ASA Placebo Daily for six weeks.

Protocol No.: M10-229 Date: December 31, 2007

Evaluation of Choline Fenofibrate (ABT-335) on Carotid Antima-Media Thickness (cIMT) in Subjects with Type IIa and Iib Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) Treatment.

Protocol No.: M10-158 Date: February 14, 2008

Efficacy and Tolerability of Nebivolol Compared with Carvedilol in Patients with Coronary Artery Disease and Stage 1 and 2 Hypertension.

Protocol No.: NEB-MD-06 Date: May 7, 2008

A Multicenter Prospective, Randomized, Double Blind, Placebo-Controlled, Dose Titration Study of Nebivolol Monotherapy in Hispanic Patients with Stage 1 or Stage 2 Hypertension.

Protocol No.: NEB-MD-16 Date: November 28, 2008

Telmisartan 80mg plus Amlodipine 10mg Fixed Dose Combination Tablet Study versus Amlodipine 10mg Over-Encapsulated Tablets as First Line Therapy in Patients with Type 2 Diabetes Mellitus and Stage 1 or 2 Hypertension: A Phase 3, Eight Week, Randomized, Double-Blind, Double-Dummy, Forced Titration Comparison.

Protocol No.: 1235.21 Date: 2009

A Multicenter, Randomized, Double-blind, Active-Controlled Study to Evaluate the Durability of the Efficacy and Safety of Alogliptin Compared to Glipizide when used in Combination with Metformin in Subjects with Type 2 Diabetes  
Protocol: SYR-322-305 Date: February 24, 2009

A Randomized, Double-Blind, Active-Comparator, 8-Week Forced-Titration Study of the Efficacy and Safety of Olmesartan Medoxomil versus Losartan Potassium in Hypertensive Subjects  
Protocol No: CS0886-A-U452 Date: June 16, 2009

A Double-Blind, Active Controlled Long Term Safety Extension Study of Optimized Doses of Darusentan in Subjects with Resistant Hypertension despite receiving Combination Therapy with three or more Anti Hypertensive Drugs, including a Diuretic, as Compared to Guanfacine.  
Protocol No.: DAR-312-E Date: July 2009

A Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate Cardiovascular Outcomes following Treatment with Alogliptin in addition to Standard of Care in Subjects with Type 2 Diabetes and Acute Coronary Syndrome ("Study")  
Protocol No: SYR 322-402 Date: October 10, 2009

Glycemic Effects of Nebivolol Compared with Metoprolol Extended Release and Compared with Hydrochlorothiazide in Hypertensive Patients with Type 2 Diabetes Mellitus: A Pilot Study  
Protocol No.: NEB-MD-19 Date: November 18, 2009

Telmisartan 80mg plus Amlodipine 10mg Fixed Dose Combination Tablet Study versus Amlodipine 10mg over Encapsulated Tablets or Telmisartan 80mg Tablets as First Line Therapy in Patients with Severe Hypertension: A Phase III 8 Week Randomized, Double-Blind, Double-Dummy, Forced-Titration Comparison (TEAMSTA Severe Hypertension).  
Protocol No.: 1235.20 Date: April 15, 2010

A Randomized, Double-Blind, Parallel-Group Study to Evaluate the Effects of First Line Treatment with a Free Combination of Nebivolol and Lisinopril Compared with Placebo and the Monotherapy Components on Blood Pressure in Patients with Stage 2 Diastolic Hypertension.  
Protocol No.: NEB-MD-25 Date: August 18, 2010

A Prospective, Randomized, Open-Label, Active-Comparator, Blinded-Endpoint, 12-Week Forced Titration Study of the Efficacy and Safety of Nebivolol versus Metoprolol and Hypertensive Subjects taking Amlodipine.

Protocol No.: BYS-MD-48 Date: August 30, 2010

A Multi-Center, International , Randomized, Parallel Group, Double-Blind Study to Evaluate Cardiovascular Safety of Linagliptin versus Glimepiride in Patients with Type 2 Diabetes Mellitus at High Cardiovascular Risk. The Carolina Trial

Protocol No: 1218.74 Date: February 16, 2011

A Phase 2 Double-Blind Randomized Placebo and Active Controlled Dose Finding Study to Assess the Efficacy, Safety and Tolerability of Multiple Oral Doses of ASP1941 in Subjects with Type 2 Diabetes Mellitus.

Protocol No.: 1941-CL-0004 Date: July 29, 2011

A Multicenter, Randomized Double-Blind Placebo Controlled, 8 Week Study to Evaluate the Safety and Efficacy of Nebivolol and Valsartan given as a Fixed Dose Combination in Patients with Stage 1 and 2 Essential Hypertension.

Protocol No.: NAC-MD-01 Date: 2012

A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80mg once daily Compared to Placebo on Ambulatory Blood Pressure in Subjects with Hyperuricemia and Hypertension.

Protocol No.: TMX-67-206 Date: April 12, 2012

A Prospective, Open Label Blinded- Endpoint, 4-6 Week Study of the Efficacy and Safety of Tribenzor in Hypertensive Subjects.

Protocol No.: PMC-52-005 Date: July 16, 2012

A Phase 3, Randomized Double -Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Favipiravir in Adult Subject with Uncomplicated Influenza ("Study")

Date: October 1, 2013

A Phase 3, Randomized, Double Blind, Multicenter Placebo, Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40mg XR, 80mg XR, 40mg IR, and 80mg IR in Subjects with Gout

Protocol No: FEB-XR-301 Date: August 11, 2014

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of Empagliflozin (10mg, 25mg) Administered Orally, once daily over 24 Weeks in Hypertensive Black/African American Patients with Type 2 Diabetes Mellitus.  
Protocol No.: 1245.29 Date: August 27, 2014

SPRINT Study NIH  
Systolic Blood Pressure Intervention Trial  
Date: 2015

A 52 Week, Phase 3 Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study to Assess the Efficacy, Safety and Tolerability of PF-04950615 in Subjects with Primary Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events.  
Protocol No.: B1481045 Date: April 8, 2015

A Phase 3, Randomized, Double-Blind, Multicenter Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40mg XR, 80mg XR, 40mg IR and 80mg IR in Subjects with Gout.  
Protocol No.: FEB-XR-301 Date: April 29, 2015

Pharmacodynamic Equivalence Study of Ramipril 10mg and Atorvastatin 40mg Administered as a Cardiovascular Fixed Dose Combination Pill AAR as Compared to Monotherapy with the Reference Products Altace 10mg and Lipitor 40mg.  
Date: January 26, 2016

Multicenter, Double-Blind, Double-Dummy, Randomized, Placebo and Active-Reference, Parallel Group, Phase 2 Dose-Finding Study with ACT-132577 in Subjects with Essential Hypertension (grade 1 and 2)  
Protocol No.: AC-080-A201 Date: February 8, 2016

Double-Blind, Randomized, Placebo Controlled Parallel-Group, Phase 4 Study to Evaluate the Effect of Aclidinium Bromide on Long Term Cardiovascular Safety and COPD Exacerbations in Patients with Moderate to Very Severe COPD (Ascent COPD).  
Protocol No.: LAS-MD-45 Date: March 28, 2016

A Prospective, Randomized Open-Label, 13 to 14 Week Study of the Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Subject with Left Ventricular Hypertrophy (LVH).  
Protocol No.: BYS-IT-78 Date: February 2, 2017

Renal Denervation using the Vessex Reduce Catheter and Vessix Generator for the Treatment of Hypertension: REINFORCE.

Date: February 21, 2017

Survey of Patients with Resistant Hypertension / Protocol for a Multicentre Survey of Patients with Treatment Resistant Hypertension.

Date: May 8, 2017

Systolic Blood Pressure Intervention Trial: Alzheimer's, Seniors, and Kidneys (Sprint ASK).

Date: February 9, 2018

The Chymase Angiotensin (1-12) Axis in Cardiovascular Disease and Diabetes.

Date: January 28, 2019